Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity

Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity

Abstract Background The addition of high-dose cytarabine to the treatment of mantle cell lymphoma (MCL) has significantly prolonged survival of patients, but relapses are common and are normally associated with increased resistance. To elucidate the mechanisms responsible for cytarabine resistance,...

Full description

Bibliographic Details
Main Authors: Catja Freiburghaus, Venera Kuci Emruli, Angelica Johansson, Christian Winther Eskelund, Kirsten Grønbæk, Roger Olsson, Fredrik Ek, Mats Jerkeman, Sara Ek
Format: Article
Language:English
Published: BMC 2018-04-01
Series:BMC Cancer
Subjects:
Cytarabine
DCK
MCL
NF-κB
SPIB
Online Access:http://link.springer.com/article/10.1186/s12885-018-4346-1

Internet

http://link.springer.com/article/10.1186/s12885-018-4346-1

Similar Items